[go: up one dir, main page]

HK1226399A1 - 噠嗪衍生物及其作爲治療劑的用途 - Google Patents

噠嗪衍生物及其作爲治療劑的用途

Info

Publication number
HK1226399A1
HK1226399A1 HK16114675A HK16114675A HK1226399A1 HK 1226399 A1 HK1226399 A1 HK 1226399A1 HK 16114675 A HK16114675 A HK 16114675A HK 16114675 A HK16114675 A HK 16114675A HK 1226399 A1 HK1226399 A1 HK 1226399A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic agents
pyridazine derivatives
pyridazine
derivatives
therapeutic
Prior art date
Application number
HK16114675A
Other languages
English (en)
Inventor
Abreo Melwyn
Chafev Mikhail
Chakka Nagasree
Chowdhury Sultan
Fu Jian-Min
W Gschwend Heinz
W Holladay Mark
Hou Duanjie
Kamboj Rajender
Kodumuru Vishnumurthy
Li Wenbao
Liu Shifeng
Raina Vandna
Sun Sengen
Sun Shaoyi
Sviridov Serguei
Tu Chi
D Winther Michael
Zhang Zaihui
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34120234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1226399(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of HK1226399A1 publication Critical patent/HK1226399A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK16114675A 2003-07-30 2016-12-23 噠嗪衍生物及其作爲治療劑的用途 HK1226399A1 (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US49109503P 2003-07-30 2003-07-30
US54689804P 2004-02-23 2004-02-23
US54693404P 2004-02-23 2004-02-23
US54678604P 2004-02-23 2004-02-23
US54682004P 2004-02-23 2004-02-23
US54681504P 2004-02-23 2004-02-23
US55349104P 2004-03-16 2004-03-16
US55340404P 2004-03-16 2004-03-16
US55344604P 2004-03-16 2004-03-16
US55341604P 2004-03-16 2004-03-16
US55340304P 2004-03-16 2004-03-16

Publications (1)

Publication Number Publication Date
HK1226399A1 true HK1226399A1 (zh) 2017-09-29

Family

ID=34120234

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07101166.9A HK1097256A1 (en) 2003-07-30 2007-02-01 Pyrizdazine derivatives and their use as therapeutic agents
HK16114675A HK1226399A1 (zh) 2003-07-30 2016-12-23 噠嗪衍生物及其作爲治療劑的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07101166.9A HK1097256A1 (en) 2003-07-30 2007-02-01 Pyrizdazine derivatives and their use as therapeutic agents

Country Status (23)

Country Link
US (1) US7335658B2 (zh)
EP (3) EP1648874B1 (zh)
JP (1) JP4808616B2 (zh)
KR (1) KR100934554B1 (zh)
AR (1) AR047557A1 (zh)
AT (1) ATE527242T1 (zh)
AU (2) AU2004261252C1 (zh)
CA (1) CA2533899C (zh)
CY (1) CY1112178T1 (zh)
DK (1) DK1648874T3 (zh)
EC (1) ECSP066313A (zh)
ES (2) ES2568769T3 (zh)
HK (2) HK1097256A1 (zh)
HR (1) HRP20110974T1 (zh)
IL (1) IL173395A (zh)
MA (1) MA28011A1 (zh)
NO (1) NO332822B1 (zh)
NZ (1) NZ545265A (zh)
PL (1) PL1648874T3 (zh)
PT (1) PT1648874E (zh)
TN (1) TNSN06034A1 (zh)
TW (2) TW201038270A (zh)
WO (1) WO2005011655A2 (zh)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7390813B1 (en) * 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
AU2004261268B2 (en) * 2003-07-30 2009-03-12 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
JP4831577B2 (ja) * 2003-07-30 2011-12-07 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリダジン誘導体および治療剤としての用途
AU2004261252C1 (en) 2003-07-30 2009-09-17 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
CA2553968A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
CA2580762A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CA2580781A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
CN101083994A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
AR051091A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
JP2008513515A (ja) 2004-09-20 2008-05-01 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
MX2007003330A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
AR051093A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
WO2006125179A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
WO2006125180A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperazine derivatives and their uses as therapeutic agents
WO2007044085A2 (en) * 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
MX2007015216A (es) * 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
CN101203244A (zh) * 2005-07-01 2008-06-18 诺瓦提斯公司 肾素抑制剂和胰岛素分泌促进剂或胰岛素敏化剂的组合产品
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
US7799787B2 (en) * 2005-12-20 2010-09-21 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
WO2007136746A2 (en) * 2006-05-19 2007-11-29 Xenon Pharmaceuticals Inc. Macrocyclic compounds and their uses as stearoyl-coa desaturase
PL2029572T3 (pl) 2006-06-05 2011-05-31 Novartis Ag Związki organiczne
KR20090040478A (ko) 2006-08-24 2009-04-24 노파르티스 아게 ２-(피라진-２-일)-티아졸 및 ２-(１Ｈ-피라졸-３-일)-티아졸 유도체, 및 대사, 심혈관 및 기타 장애의 치료를 위한 스테아로일-ＣｏＡ 데새투라제(ＳＣＤ) 억제제로서의 관련 화합물
US8246433B2 (en) * 2006-08-25 2012-08-21 Alma Mater Sports, Llc Team based fantasy sport contest
WO2008056687A1 (fr) * 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Nouveau dérivé de spiropipéridine
AU2007323193A1 (en) * 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Acetylene derivatives as Stearoyl CoA Desaturase inhibitors
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP2010520162A (ja) * 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体
CA2682671C (en) * 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
DK2148873T3 (da) * 2007-04-23 2012-11-26 Janssen Pharmaceutica Nv 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister
MY148657A (en) 2007-04-27 2013-05-15 Purdue Pharma Lp Trpv1 antagonists and uses thereof
EP2572712A3 (en) 2007-06-01 2013-11-20 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2008157844A1 (en) 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
JP5239001B2 (ja) 2007-08-08 2013-07-17 メディシス・ファーマシューティカル・コーポレーション フェノキシ−ピロリジン誘導体ならびにその使用および組成物
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
AU2008334705B2 (en) * 2007-12-11 2011-06-16 F. Hoffmann-La Roche Ag Inhibitors of stearoyl-CoA desaturase
US8895562B2 (en) * 2008-07-31 2014-11-25 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
WO2010094120A1 (en) 2009-02-17 2010-08-26 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2459568A4 (en) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd NOVEL SPIRO COMPOUNDS USEFUL AS DELTA-9 DEATURASE STEAROYL COENZYME INHIBITORS
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2011030312A1 (en) 2009-09-10 2011-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
JP2013507366A (ja) 2009-10-09 2013-03-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性モジュレーターとしての化合物および組成物
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
ES2620528T3 (es) 2011-06-22 2017-06-28 Purdue Pharma Lp Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos
KR20140084164A (ko) 2011-10-15 2014-07-04 제넨테크, 인크. 암의 치료를 위한 scd1 길항제
AU2013241854B2 (en) * 2012-03-28 2017-11-02 Intervet International B.V. Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection
JP6293127B2 (ja) 2012-05-22 2018-03-14 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド 未分化細胞の選択的阻害剤
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
DK3350165T3 (da) 2015-09-16 2023-09-25 Organovo Inc Farnesoid-X-receptoragonister og anvendelser deraf
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
BR112019013954A2 (pt) 2017-01-06 2020-02-11 Yumanity Therapeutics, Inc. Métodos para o tratamento de distúrbios neurológicos
AU2018236275B2 (en) 2017-03-15 2022-05-12 Organovo, Inc. Farnesoid X receptor agonists and uses thereof
EP3596053B1 (en) 2017-03-15 2023-08-16 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
SG11202009280RA (en) 2018-03-23 2020-10-29 Yumanity Therapeutics Inc Compounds and uses thereof
AU2019265268C1 (en) 2018-05-09 2022-08-04 Lg Chem, Ltd. Novel compound exhibiting enteropeptidase inhibitory activity
TWI833805B (zh) 2018-09-18 2024-03-01 美商奧加諾沃公司 類法尼醇x(farnesoid x)受體促效劑及其用途
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US667452A (en) * 1900-09-08 1901-02-05 John A Hendrickson Computing attachment for pumps.
US2985657A (en) * 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
AT340933B (de) * 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
EP0354920A1 (en) 1987-04-03 1990-02-21 The Upjohn Company Amino-9,10-secosteroids
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5166147A (en) * 1990-07-09 1992-11-24 The Du Pont Merck Pharmaceutical Company 4-heteroaryl-and 4-aryl-1,4-dihydropyridine, derivatives with calcium agonist and alpha1 -antagonist activity
GB9019143D0 (en) * 1990-09-01 1990-10-17 Bp Chem Int Ltd Thixotropic compositions
EP0520292A1 (de) 1991-06-19 1992-12-30 Hoechst Aktiengesellschaft Chirale Azetidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
KR100443893B1 (ko) * 1996-01-15 2004-10-15 얀센 파마슈티카 엔.브이. 혈관형성억제제피리다진아민
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH107572A (ja) * 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
WO1999000386A1 (en) 1997-06-27 1999-01-07 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
ES2189404T3 (es) 1998-03-19 2003-07-01 Upjohn Co 1,3,4-tiadiazoles utiles para el tratamiento de infecciones por cmv.
CN1329614A (zh) * 1998-10-21 2002-01-02 武田药品工业株式会社 稠合的哒嗪衍生物、它们的制备方法和用途
AU1455500A (en) 1998-10-29 2000-05-22 Trega Biosciences, Inc. Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
WO2000044743A1 (fr) 1999-01-28 2000-08-03 Nippon Shinyaku Co., Ltd. Derives d'amides et compositions de medicaments
CZ20012716A3 (cs) 1999-01-29 2001-11-14 Abbott Laboratories Diazabicyklické deriváty jako ligandy nikotinového receptoru acetylcholinu
DK1035115T3 (da) 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
BR0009650A (pt) 1999-04-09 2002-01-02 Meiji Seika Kaisha Composto, composição farmacêutica, processos para inibir a secreção de uma lipoproteìna contendo apolipoproteìna b, para inibir a biossìntese de triglicerìdeos e para prevenir ou tratar hiperlipidemia, doenças arterioscleróticas e pancreatite, e, uso do composto
JP3637961B2 (ja) * 1999-09-16 2005-04-13 田辺製薬株式会社 芳香族含窒素六員環化合物
US6677452B1 (en) 1999-09-30 2004-01-13 Lion Bioscience Ag Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
WO2001043746A1 (fr) 1999-12-14 2001-06-21 Nippon Shinyaku Co., Ltd. Composition medicinale
AU4722801A (en) * 2000-02-24 2001-09-03 Xenon Genetics Inc Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
JP2003527379A (ja) 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
WO2002010154A2 (en) * 2000-07-27 2002-02-07 Eli Lilly And Company Substituted heterocyclic amides
AU2001289457A1 (en) 2000-09-26 2002-04-08 Xenon Genetics Inc. Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
DE10060412A1 (de) * 2000-12-05 2002-06-06 Bayer Ag DELTA1-Pyrroline
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
FR2823209B1 (fr) * 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
WO2002094799A2 (en) * 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
RU2285002C2 (ru) * 2001-06-15 2006-10-10 Астеллас Фарма Инк. Производное пиридина и фармацевтическая композиция на его основе
WO2003037862A1 (fr) 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Derives amide, et medicaments correspondants
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
CA2468716A1 (en) 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
US7449457B2 (en) 2001-12-07 2008-11-11 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
IL162859A0 (en) 2002-02-05 2005-11-20 Novo Nordisk As Novel aryl-and heteroarylpiperazines
EP1485354B1 (en) 2002-03-13 2008-05-28 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
MXPA04008797A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Inhibidores de histona desacetilasa.
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
JP2005537228A (ja) 2002-04-25 2005-12-08 ファルマシア・コーポレーション ピペリジニル−及びピペラジニル−スルホニルメチルヒドロキサム酸並びにプロテアーゼ阻害剤としてのその使用
WO2004010927A2 (en) 2002-07-25 2004-02-05 Wisconsin Alumni Research Foundation Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
PL377215A1 (pl) 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
JP2004203871A (ja) 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
AU2004261268B2 (en) 2003-07-30 2009-03-12 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
AU2004261252C1 (en) 2003-07-30 2009-09-17 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
JP4831577B2 (ja) * 2003-07-30 2011-12-07 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリダジン誘導体および治療剤としての用途

Also Published As

Publication number Publication date
EP3042895A1 (en) 2016-07-13
IL173395A (en) 2013-03-24
AU2009201788B2 (en) 2012-04-05
CA2533899C (en) 2011-01-04
TW201038270A (en) 2010-11-01
JP2007500717A (ja) 2007-01-18
PT1648874E (pt) 2011-12-23
AU2004261252C1 (en) 2009-09-17
AU2004261252B2 (en) 2009-02-05
NZ545265A (en) 2009-11-27
AR047557A1 (es) 2006-01-25
DK1648874T3 (da) 2012-01-23
PL1648874T3 (pl) 2012-04-30
CY1112178T1 (el) 2015-12-09
TNSN06034A1 (en) 2007-10-03
JP4808616B2 (ja) 2011-11-02
KR20060036107A (ko) 2006-04-27
EP1648874B1 (en) 2011-10-05
WO2005011655A2 (en) 2005-02-10
KR100934554B1 (ko) 2009-12-29
TW200518753A (en) 2005-06-16
EP2316827B1 (en) 2016-01-27
ES2375134T3 (es) 2012-02-27
HK1097256A1 (en) 2007-06-22
AU2009201788A1 (en) 2009-05-28
IL173395A0 (en) 2006-06-11
US7335658B2 (en) 2008-02-26
AU2004261252A1 (en) 2005-02-10
EP1648874A2 (en) 2006-04-26
WO2005011655A3 (en) 2005-03-24
EP2316827A1 (en) 2011-05-04
MA28011A1 (fr) 2006-07-03
NO332822B1 (no) 2013-01-21
NO20060981L (no) 2006-05-02
HRP20110974T1 (hr) 2012-01-31
ATE527242T1 (de) 2011-10-15
US20050065143A1 (en) 2005-03-24
ES2568769T3 (es) 2016-05-04
CA2533899A1 (en) 2005-02-10
ECSP066313A (es) 2006-07-28
TWI345974B (en) 2011-08-01

Similar Documents

Publication Publication Date Title
HK1226399A1 (zh) 噠嗪衍生物及其作爲治療劑的用途
IL173398A0 (en) Pyridyl derivatives and their use as therapeutic agents
SG145699A1 (en) Pyridazine derivatives and their use as therapeutic agents
TWI349551B (en) Thiophenepyrimidinone derivatives and their use in therapy
GB0307918D0 (en) Therapeutic use
GB0324761D0 (en) Use of compounds in therapy
HRP20041157A2 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
GB0615918D0 (en) Composition and its therapeutic use
GB0219660D0 (en) Therapeutic use
GB0207410D0 (en) Compounds and their therapeutic use
EP1601348A4 (en) Compositions and methods with improved therapeutic activity
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
AU2003205963A8 (en) Azaphenylalanine derivatives and their use as antithrombotic agents
GB0327050D0 (en) Therapeutic methods compositions and uses
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
GB0307333D0 (en) Therapeutic agent
SG145720A1 (en) Pyridazine derivatives and their use as therapeutic agents
IL165420A0 (en) Piperazinylacylpiperidine derivatives their preparation and therapeutic use thereof
GB0215773D0 (en) Compunds and their therapeutic use
GB0306444D0 (en) Composition and its therapeutic use
GB0203042D0 (en) Anthraquinine compounds their preparation and their use in therapy
GB0203043D0 (en) Benzimidazloe compounds their preparation and their use in therapy
GB0210898D0 (en) Pyridinecarbonitrile compounds and their therapeutic use
GB0225688D0 (en) Therapeutic compounds and their use in therapy
AU2003907195A0 (en) Therapeutic agents and uses therefor